All In Biotech

Drug Trial Radar · NCT05287308

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study

Last checked: Nov 20, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Mar 2022

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Chinese Academy of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CSPC Ouyi Pharmaceutical Co., Ltd.
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Conditions

  • Breast Cancer

Interventions

  • doxorubicinDrug

    doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.

  • epirubicinDrug

    epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.

  • pirarubicinDrug

    pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.

  • cyclophosphamideDrug

    cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.

  • albumin-bound paclitaxelDrug

    albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.

  • paclitaxelDrug

    paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.

  • docetaxelDrug

    docetaxel 80\~100mg/m2, i.v., d1, q3w.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-year invasive disease-free survival (IDFS) rateTime frame: up to 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, ChineseAMS

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.